Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GLPG 
Galapagos NV ADR (GLPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GLPG (1-star) is a SELL. SELL since 1 days. Profits (-5.92%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.94% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.66B USD | Price to earnings Ratio - | 1Y Target Price 31.46 |
Price to earnings Ratio - | 1Y Target Price 31.46 | ||
Volume (30-day avg) 179077 | Beta -0.01 | 52 Weeks Range 22.36 - 32.17 | Updated Date 04/2/2025 |
52 Weeks Range 22.36 - 32.17 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 26.88% | Operating Margin (TTM) -81.43% |
Management Effectiveness
Return on Assets (TTM) -2.75% | Return on Equity (TTM) -0.05% |
Valuation
Trailing PE - | Forward PE 166.67 | Enterprise Value -1702596540 | Price to Sales(TTM) 6.02 |
Enterprise Value -1702596540 | Price to Sales(TTM) 6.02 | ||
Enterprise Value to Revenue 1.18 | Enterprise Value to EBITDA -31.5 | Shares Outstanding 65897100 | Shares Floating 44547738 |
Shares Outstanding 65897100 | Shares Floating 44547738 | ||
Percent Insiders - | Percent Institutions 48.15 |
Analyst Ratings
Rating 3.12 | Target Price 29.45 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 6 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Galapagos NV ADR
Company Overview
History and Background
Galapagos NV, founded in 1999, is a Belgian biotechnology company focused on the discovery and development of novel medicines. Initially focused on drug discovery services, it transitioned to developing its own proprietary drug candidates. A significant milestone was the collaboration with AbbVie on filgotinib.
Core Business Areas
- Research and Development: Focuses on discovering and developing innovative medicines in areas with high unmet medical need, primarily in inflammation, fibrosis, and other disease areas.
- Commercialization: Currently focused on commercializing Jyseleca (filgotinib) in Europe and potentially other regions, where approved, and focusing on the continued development of the pipeline.
Leadership and Structure
The leadership team is led by Dr. Paul Stoffels as CEO. The company has a board of directors and operates with a functional organizational structure focused on R&D, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- Jyseleca (filgotinib): A selective JAK1 inhibitor approved in Europe and Japan for rheumatoid arthritis and ulcerative colitis. AbbVie, previously a development partner, decided not to pursue FDA approval. Market share varies by country in Europe; facing competition from other JAK inhibitors and biologics. Competitors: AbbVie (Rinvoq), Eli Lilly (Olumiant), Pfizer (Xeljanz).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Biotechnology companies are increasingly focused on developing targeted therapies. The autoimmune disease market is a major driver, with continuous innovation in biologics and small molecules.
Positioning
Galapagos is positioning itself as an innovative biotech company focused on novel drug discovery and development, leveraging its platform and expertise. Its competitive advantage lies in its R&D capabilities and unique targets.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapies is estimated to be over $100 billion. Galapagos is positioned to capture a portion of this market through its current and future pipeline.
Upturn SWOT Analysis
Strengths
- Strong research and development capabilities
- Innovative drug discovery platform
- Strategic partnerships
- Established presence in Europe
Weaknesses
- Dependence on key partnerships (e.g., AbbVie)
- Commercialization challenges
- Pipeline risk associated with drug development
- Limited US presence after AbbVie's decision on filgotinib
Opportunities
- Expansion of pipeline through internal R&D
- New partnerships for drug development and commercialization
- Expansion into new therapeutic areas
- Potential regulatory approvals in new markets
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval delays
- Clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- ABBV
- LLY
- PFE
- BMY
Competitive Landscape
Galapagos faces competition from large pharmaceutical companies with greater resources and established market presence. Its advantage lies in novel targets and its R&D capabilities, but faces commercial risks.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Galapagos's growth has been driven by its R&D efforts and partnerships. The success of Jyseleca has been a factor in previous years, but with AbbVie dropping it in the US, growth prospects are now tied to the pipeline
Future Projections: Future growth is dependent on the success of its pipeline. Analyst estimates vary based on trial results and regulatory approvals.
Recent Initiatives: Galapagos is focused on advancing its pipeline, exploring new targets, and potentially seeking new partnerships. They also focusing on commercializing Jyseleca.
Summary
Galapagos is a biotech company with a promising R&D pipeline, but faces commercialization challenges and heavy reliance on partnerships. Their innovative drug discovery platform provides a strong foundation, yet competition and regulatory hurdles pose significant risks. Pipeline advancement and successful commercialization strategies are crucial for its future success. AbbVie abandoning their drug in the US hurt their growth opportunities and shareholder value.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galapagos NV ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2005-05-06 | CEO, Chairman, Interim Head of R&D Dr. Paulus A. Stoffels M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 704 | Website https://www.glpg.com |
Full time employees 704 | Website https://www.glpg.com | ||
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.